Treatment of Ulcerative Colitis with a Humanized Antibody to the α <sub>4</sub> β <sub>7</sub> Integrin
Brian G. Feagan(Western University), Margaret K. Vandervoort(Western University), Richard N. Fedorak(University of Alberta), Gary Wild(Montreal General Hospital), Rasha Aguzzi(Millennium Engineering and Integration (United States)), A. Hillary Steinhart(Mount Sinai Hospital), Réjean Dubé(Université Laval), Steven B. Landau(ImmunoGen (United States)), Gordon R. Greenberg(University of Toronto), John WD McDonald, Pierre Paré(Université Laval), Albert Cohen(Jewish General Hospital), Irving H. Fox(Takeda (United States))
Cited by 694
Related Papers
Infliximab for Induction and Maintenance Therapy for Ulcerative Colitis
|New England Journal of Medicine|2005|3.9k
A Genome-Wide Association Study Identifies <i>IL23R</i> as an Inflammatory Bowel Disease Gene
|Science|2006|3k
Vedolizumab as Induction and Maintenance Therapy for Ulcerative Colitis
|New England Journal of Medicine|2013|2.9k
Vedolizumab as Induction and Maintenance Therapy for Crohn's Disease
|New England Journal of Medicine|2013|2.7k
Genome-wide association defines more than 30 distinct susceptibility loci for Crohn's disease
|Nature Genetics|2008|2.6k